Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

25

Revenue 2017

Genvoya

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Genvoya was produced by Gilead Sciences.

MSD claims EU approval for two HIV products

MSD claims EU approval for two HIV products

In the US, Merck has priced Delstrigo at $70 per day, at the low end of rivals such as Gilead’s Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) and ViiV’s Triumeq

Gilead plans fightback against HIV arch-rival ViiV

Gilead plans fightback against HIV arch-rival ViiV its Genvoya and Stribild products - which needs to be boosted with cobicistat.

Gilead gets EU nod for TAF-based triple therapy for HIV

Gilead gets EU nod for TAF-based triple therapy for HIV also bagged approval for four-drug Genvoya (elvitegravir, emtricitabine, cobicistat and TAF), an updated version of the company's $1.8bn Stribild brand. ... In the first 18 weeks from launch in the US last November, Genvoya's uptake is outpacing Gilead's

Gilead bags EU approval for next-generation HIV drug

Gilead bags EU approval for next-generation HIV drug Four-drug product Genvoya (elvitegravir, emtricitabine, cobicistat and TAF) was approved in its first markets last year and is positioned to replace Gilead's $1.8bn Stribild brand.

Gilead boosts liver disease pipeline with $1.2bn acquisition

Gilead boosts liver disease pipeline with $1.2bn acquisition Descovy is the third TAF-based HIV drug in Gilead's portfolio - joining its other once-daily treatments Genvoya and Odefsey - and adds to the biopharmaceutical firm's dominance in the

1 2 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics